Qureight Raises £1.5M in Seed Funding

Qureight, a Cambridge, UK-based data company focusing on complex diseases, raised £1.5m in seed funding.

The round was led by Playfair Capital, with participation from Life Sciences funds Meltwind, Ascension and Cambridge Angels.

The company intends to use the funds to continue to expand operations and its business reach.

Led by CEO Dr. Muhunthan Thillai, and Chief Scientific Officer Dr. Alessandro Ruggiero, Qureight is a company which uses cloud-based technology to assist in the structuring of image and paired clinical metadata in complex diseases. By structuring data in this way, it allows for the development of AI-based tools to understand diseases including lung fibrosis, complex cancers and covid-19. Clients using the platform include the drug companies Takeda, Galapagos and Roche.